Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease

被引：3
|
作者：
Park, Yea Eun [1 ]
Chong, Yong Pil [2 ]
Lee, Hyun Joo [3 ]
Shim, Tae Sun [1 ]
Jo, Kyung-Wook [1 ]
机构：
[1] Univ Ulsan, Div Pulmonol & Crit Care Med, Dept Internal Med, Asan Med Ctr,Coll Med, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Infect Dis, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 12期
基金：
新加坡国家研究基金会;
关键词：
cavitary MAC-PD; clofazimine; moxifloxacin;
D O I：
10.1128/aac.00528-22
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
In this retrospective analysis including 173 patients in a tertiary referral center in South Korea, compared with the standard therapeutic regimen, clofazimine or moxifloxacin plus standard treatment regimen potentially did not induce a higher 1-year culture conversion rate in patients with Mycobacterium avium complex pulmonary disease who present with cavitary lesions (fibrocavitary or cavitary nodular bronchiectatic type).
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Isolated Pulmonary Mycobacterium Avium Complex Presenting As A Cavitary Mass In A Man With Aids
    Arredondo, A. F.
    Eshaghian, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [32] Residual Destructive Lesions and Surgical Outcome in Mycobacterium avium Complex Pulmonary Disease
    Togo, Takeo
    Atsumi, Jun
    Hiramatsu, Miyako
    Shimoda, Kiyomi
    Morimoto, Kozo
    Uchimura, Kazuhiro
    Shiraishi, Yuji
    ANNALS OF THORACIC SURGERY, 2020, 110 (05): : 1698 - 1705
  • [33] Treatment of Mycobacterium avium Complex Pulmonary Disease
    Kwon, Yong-Soo
    Koh, Won-Jung
    Daley, Charles L.
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2019, 82 (01) : 15 - 26
  • [34] Familial pulmonary Mycobacterium avium complex disease
    Tanaka, E
    Kimoto, T
    Matsumoto, H
    Tsuyuguchi, K
    Suzuki, K
    Nagai, S
    Shimadzu, M
    Ishibatake, H
    Murayama, T
    Amitani, R
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (05) : 1643 - 1647
  • [35] Treatment of Mycobacterium avium complex pulmonary disease
    Jhun, Byung Woo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2024, 67 (01): : 19 - 25
  • [36] Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy
    BrownHarrell, V
    Nitta, AT
    Goble, M
    CLINICAL INFECTIOUS DISEASES, 1996, 22 (03) : 581 - 582
  • [37] Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Baek, Sun-Young
    Sohn, Insuk
    Jhun, Byung Woo
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 12
  • [38] Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease
    Park, Yea Eun
    Chong, Yong Pil
    Kim, Ye-Jee
    Kim, Ock-Hwa
    Kwon, Byoung Soo
    Shim, Tae Sun
    Jo, Kyung-Wook
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 338 - 348
  • [39] Preliminary Evaluation Of A Sitafloxacin - Containing Regimen For Relapsed Or Refractory Pulmonary Mycobacterium Avium Complex Disease
    Fujita, K.
    Fujita, M.
    Ito, Y.
    Hirai, T.
    Mio, T.
    Watanabe, K.
    Mishima, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [40] Mycobacterium shimoidei-cavitary pulmonary disease with favorable outcome
    Popovic, Vide
    Arar, Dragan
    Popovic, Dragica Roso
    Barisic, Igor
    Tonkic, Marija
    Peric, Irena
    Novak, Anita
    Rubic, Zana
    Katalinic-Jankovic, Vera
    Makek, Mateja Jankovic
    Goic-Barisic, Ivana
    FOLIA MICROBIOLOGICA, 2018, 63 (02) : 249 - 252
12345